Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients

BACKGROUND: Neutralizing monoclonal antibodies (mAbs) were authorized for the treatment of COVID-19 outpatients based on clinical trials completed early in the pandemic, which were underpowered for mortality and subgroup analyses. Real-world data studies are promising for further assessing rapidly d...

Descripción completa

Detalles Bibliográficos
Autores principales: Wynia, Matthew K., Beaty, Laurel E., Bennett, Tellen D., Carlson, Nichole E., Davis, Christopher B., Kwan, Bethany M., Mayer, David A., Ong, Toan C., Russell, Seth, Steele, Jeffrey D., Stocker, Heather R., Wogu, Adane F., Zane, Richard D., Sokol, Ronald J., Ginde, Adit A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Chest Physicians. Published by Elsevier Inc. 2023
Materias:
Chest Infections: Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613796/
https://www.ncbi.nlm.nih.gov/pubmed/36441040
http://dx.doi.org/10.1016/j.chest.2022.10.020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613796/
https://www.ncbi.nlm.nih.gov/pubmed/36441040
http://dx.doi.org/10.1016/j.chest.2022.10.020

Ejemplares similares